Stem Cell Therapy for Post-Myocardial Infarction Heart Failure

Terapi Sel Punca untuk Gagal Jantung Pasca Infark Miokard

Heart failure occurring after a myocardial infarction (heart attack) is a serious, life-threatening condition.

With current treatments, although symptoms can be alleviated, damaged cardiac muscle (myocardium) cannot be restored to its original state. Therefore, in recent years, regenerative therapy utilizing stem cells has garnered attention as a novel approach.

This advanced therapy unlocks the potential to "repair damaged hearts from within."

Post-Myocardial Infarction Heart Failure: Realities and Limitations

The risk of developing heart failure after myocardial infarction is high, and because conventional treatment cannot restore damaged heart muscle, expectations for regenerative therapy are rising.

Why Does Heart Failure Occur After Myocardial Infarction?

Following a myocardial infarction, many patients face a persistent risk of developing chronic heart failure. Although advancements in medical technology have improved survival rates following myocardial infarction, the reality is that the number of survivors who develop heart failure continues to rise.

Specifically, in patients with severe heart failure, the 5-year survival rate is reported to be approximately 50%, comparable to the survival rate for cancer—a disease with a very serious prognosis.

Limitations of Conventional Heart Failure Treatment

Current heart failure treatment focuses on symptom management as follows:

  • Terapi farmakologis:ACE inhibitors, beta-blockers, etc. to reduce the strain on the heart.
  • Rekonstruksi aliran darah:Catheter or bypass surgery to increase blood flow
  • Terapi perangkat:Pacemaker or artificial heart to support the pumping function

However, this entire process does not involve the restoration of the necrotic myocardial tissue itself. The dead portion becomes scar tissue and remains unable to contribute to the heart's pumping function.

Consequently, an excessive load is placed on the remaining normal myocardium, leading to the eventual fatigue of these healthy cells and the continued progression of heart failure.

Heart Transplantation: A Treatment of Last Resort, Yet Impractical

Heart transplantation can be a definitive treatment, but there are practical obstacles:

  • Chronic donor shortage
  • Risk of major surgery
  • Lifelong burden of immunosuppressive therapy

Due to these practical constraints, only a small fraction of patients can undergo this surgery.

New Hope: A Treatment for Cardiac Regeneration

Consequently, the era of being compelled to accept a failing heart has concluded, and the prospects for regenerative therapies to repair damaged myocardium have surged.

Notably, Stem Cell Therapy is gaining traction as a next-generation therapeutic option.

Key Point

  • The incidence of heart failure post-myocardial infarction is rising, with a 5-year survival rate of approximately 50%.
  • Conventional treatment cannot regenerate damaged cardiac muscle and is unable to completely halt the progression of heart failure.
  • Heart transplantation is theoretically a definitive treatment, but in practice, options are limited.
  • The demand for regenerative therapies designed to repair damaged hearts is rapidly increasing.

New Possibilities of Stem Cell Therapy for Addressing Post-Myocardial Infarction Heart Failure

Dead myocardial cells due to myocardial infarction cannot regenerate naturally. Stem Cell Therapy is a new option that aims to "restore lost heart function."

Following myocardial infarction, the necrotic cardiac tissue is replaced by scar tissue and permanently loses its original contractile function. This leads to a reduction in cardiac pump function and, over time, progresses to chronic heart failure.

Regenerating Dead Myocardium

Conventional treatment cannot regenerate lost myocardial tissue and only serves to alleviate the heart's workload through medication or mechanical devices. With Stem Cell Therapy, the administered cells work in the following ways to directly support the recovery of cardiac function:

  • Tetap berada di sekitar lokasi nekrosis dan mengirim sinyal promosi regenerasi miokardium
  • Mendorong angiogenesis (pembentukan kapiler baru), sehingga meningkatkan pasokan oksigen ke miokardium
  • Soothing inflammation formenghambat remodeling (penurunan) jaringan jantung

It is expected that this will not only maintain and enhance pump function, but also prevent the progression of heart failure.

Why are WJ-MSCs derived from Wharton's Jelly suitable for the heart?

Among various stem cells, umbilical cord-derived mesenchymal stem cells (Wharton's jelly MSCs) are considered suitable for cardiac treatment due to the following characteristics:

  • High angiogenesis-promoting ability:Helps myocardial oxygen supply and supports myocardial cell survival
  • Powerful anti-inflammatory actionSuppressing excessive inflammation that occurs after myocardial infarction and preventing the deterioration of the condition.
  • Immunogenisitas rendah:Easily given, even by others, and not easily rejected.

Furthermore, umbilical cord MSCs are notably naïve, and compared to senescent cells, they exhibit superior activity and enhanced regenerative potential, thus being considered more effective for myocardial tissue repair.

Key Point

  • Stem Cell Therapy is a novel approach aimed at regenerating necrotic myocardium.
  • Not only does it maintain and enhance cardiac pump function, but it also contributes to the prevention of heart failure progression.
  • Umbilical cord-derived WJ-MSCs possess potent pro-angiogenic and anti-inflammatory properties, making them well-suited for cardiac regeneration.

Mechanisms of Stem Cell Therapy Acting on the Post-Myocardial Infarction Heart

Stem Cell Therapy functions as a "repair factor factory" in the injured heart, promoting myocardial regeneration by promoting angiogenesis and inhibiting inflammation. Only a small fraction directly replaces the myocardium, but the paracrine effect (released cytokines and growth factors) plays a major role.

Stem cells function as a 'cardiac therapeutic reservoir'.

Necrotic myocardial tissue resulting from myocardial infarction has very limited capacity for spontaneous regeneration. In Stem Cell Therapy, cells administered to the heart not only directly engraft into the damaged area but also release various beneficial substances into their surroundings to promote repair.

The specific effects are as follows:

  • Promosi angiogenesis: Membentuk kapiler baru, meningkatkan pasokan oksigen dan nutrisi ke miokardium
  • Penenangan peradangan:Suppressing the excessive inflammatory response that occurs after myocardial infarction
  • Inhibition of myocardial cell deathPreventing apoptosis (programmed death) of injured myocardial cells
  • Penghambatan fibrosis (penyarutan):Inhibits wound formation, maintains flexible muscle tissue
  • Activation of intrinsic myocardial precursor cellsStimulating reserve cells hidden in the heart to promote spontaneous regeneration

In this manner, stem cells are not merely cell replacements, but rather issue healing directives to the heart from multiple angles.

Why is WJ-MSC from Wharton's Jelly promising?

Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) demonstrate significant superiority in cardiac treatment in the following aspects:

  • High secretion capacity of repair factors
    Compared to bone marrow MSCs, the production of "hepatocyte growth factor (HGF)," which promotes myocardial regeneration, is about 55 times greater. HGF is an important factor for myocardial cell survival and angiogenesis.
  • Secretion of diverse cytokines and growth factors
    Secara melimpah melepaskan VEGF (faktor pertumbuhan endotel pembuluh darah), IGF-1 (faktor pertumbuhan seperti insulin), bFGF (faktor pertumbuhan fibroblas dasar), dll, mendukung perbaikan aliran darah dan perlindungan miokardium.
  • Powerful immune regulatory action
    Suppressing the inflammatory burst after myocardial infarction and preventing tissue damage. It has been reported that WJ-MSCs suppress the proliferation of activated T cells more potently than bone marrow MSCs.

In other words, WJ-MSCs are capable of simultaneously achieving myocardial regeneration, improved blood flow, and inflammation control, thereby positioning them as "the ideal cell for heart failure."

Key Point

  • Stem cells establish a 'repair factor production facility' in the heart and provide multifaceted healing.
  • Numerous effects are anticipated, including angiogenesis, inhibition of inflammation, and myocardial protection.
  • WJ-MSCs possess high secretory and immunomodulatory capabilities and are considered ideal cells for post-myocardial infarction cardiac protection.

Is Stem Cell Therapy Truly Effective? Evidence of Cardiac Function Recovery

For post-myocardial infarction heart failure, Stem Cell Therapy has reported clear effects in clinical studies, including improved left ventricular function (LVEF), improvement in cardiac structure, and even a decrease in mortality rate.

Effect of Cardiac Function Restoration

In patients undergoing Stem Cell Therapy, a significant increase in left ventricular ejection fraction (LVEF) has been consistently reported. Specifically, in clinical trials utilizing umbilical cord-derived WJ-MSCs, LVEF at one year demonstrated an average increase of 7%, and this difference from the conventional treatment group was statistically significant.

This restores cardiac pump function, which also leads to the alleviation of heart failure symptoms such as shortness of breath and fatigue.

Protecting Cardiac Structure

In a clinical trial conducted immediately following acute myocardial infarction, the group receiving umbilical cord mesenchymal stem cells demonstrated improved blood flow at the infarct site and enhanced survival rates, as well as inhibition of cardiac enlargement (remodeling).

This indicates the potential to prevent myocardial remodeling and functional decline that commonly occur after myocardial infarction.

Enhanced Survival Rate and Reduced Readmissions

In a large-scale meta-analysis (17 trials, 1,684 participants), patients receiving MSC treatment demonstrated:

  • Mortality risk is reduced by approximately 22%.
  • Left ventricular function (LVEF) increased by an average of 3.4%.
  • The risk of rehospitalization due to heart failure also declined.

Furthermore, symptom indicators (NYHA classification) and exercise capacity (6-minute walk test) also significantly improved.

Key Point

  • Through Stem Cell Therapy, left ventricular ejection fraction (LVEF) significantly increased, and an improvement in cardiac function can be expected.
  • It is possible to suppress post-myocardial infarction cardiac enlargement (remodeling) and prevent long-term functional decline.
  • The decline in mortality rates and increase in hospitalization rates reported in clinical studies.
  • WJ-MSC specifically possesses superior regenerative and protective effects, and more potent therapeutic effects are anticipated.

Safety and Current Understanding of the Adverse Effects of Stem Cell Therapy

Although Stem Cell Therapy is an innovative treatment, clinical research so far has reported almost no serious side effects. Its safety has been confirmed in clinical trials, and regenerative therapies that can be safely administered to heart failure patients are currently being developed.

Because Stem Cell Therapy is the most advanced regenerative therapy, the verification of its safety continues to be conducted with meticulous care.

To summarize, preclinical and clinical studies to date demonstrate that Stem Cell Therapy can be safely administered to heart failure patients.

Acute Complications of Stem Cell Administration?

In clinical trials involving the intravenous administration of umbilical cord-derived MSCs, no serious adverse events were associated with the treatment. Neither allergic reactions nor shock during infusion, nor acute immune rejection reactions, occurred, and it was further demonstrated that antibodies against donor cells were not produced post-transplantation.

Therefore, unlike organ transplantation, immunosuppressant medication is not required.

On Medium to Long-Term Security

Even in long-term follow-up studies lasting over 18 months, no significant differences were observed between the Stem Cell Therapy group and the control group regarding the incidence of arrhythmias, abnormalities in tumor markers, and the mortality rate from new cancers.

In post-myocardial infarction patients, MSC treatment did not increase the risk of fatal arrhythmias or worsening heart failure, and no major safety concerns were reported compared to standard treatment.

Stem Cell Therapy and Risk of Tumor Transformation

While the risk of tumorigenesis is often a concern in novel therapeutic approaches, no tumor formation has been reported in treatments utilizing mesenchymal stem cells (MSCs).

Conversely, it has been demonstrated that MSCs possess anti-inflammatory and anti-tumor effects. No increase in cancer incidence was observed in the Stem Cell Therapy group; furthermore, a decrease was even indicated. This is attributed to MSCs' ability to suppress abnormal immune responses.

Consequently, based on clinical data accumulated to date, Stem Cell Therapy utilizing WJ-MSCs derived from Wharton's jelly is deemed to possess an exceptionally high safety profile.

Certainly, regenerative therapy is a relatively new field, and further long-term data will be required in the future. However, at present, this treatment is considered a promising therapy that can be performed without significant risks to patients.

Key Point

  • Clinical research to date has scarcely reported serious adverse events from Stem Cell Therapy.
  • Immune rejection is extremely rare, and immunosuppressants are not required.
  • No difference in arrhythmia rates, worsening heart failure, and risk of new cancer.
  • There have been no reports of tumor formation from mesenchymal stem cell therapy to date.
  • Based on clinical research findings, Stem Cell Therapy is classified as a regenerative therapy with an excellent safety profile.

Transforming the Future of Regenerative Therapy - Addressing Post-Myocardial Infarction Heart Failure

Stem Cell Therapy for post-myocardial infarction heart failure is a novel approach that repairs the injured heart from within. By challenging the previously unattainable concept of "myocardial regeneration itself" with traditional treatments, this therapy holds the potential to fundamentally transform patient longevity and quality of life.

Notably, mesenchymal stem cells derived from Wharton's jelly are attracting worldwide attention as a potent tool for next-generation heart failure treatment, due to their high regenerative capacity and favorable safety profile.

Restoring robust cardiac function to a heart damaged by myocardial infarction. Stem Cell Therapy is transforming this vision, once considered a dream, into a reality.

In ongoing clinical studies, both nationally and internationally, favorable outcomes are consistently reported, including enhanced left ventricular function, reduced risk of readmission, and improved survival rates.

Instead, serious avenues for regenerating their own hearts began to emerge, supplanting heart transplants or artificial hearts, which had previously been the sole hope.

Referensi